The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2019 | Cellular kinetics of CAR-T & prophylactic promise
Carl June
• 20 Jun 2019
Carl June, MD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, discusses the expansion and durability of CAR T-cells following treatment, as well as speculating upon their future potential to even be given prior to disease in those at high risk. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
